Skip to content
Menu

ImmuCell Corporation ICCC

Full chart Compare
Set alert

Price alert · ICCC

All alert types
10.92 USD -0.27 (-2.41%)

Regular-session close

10.92 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

10.31 Day range 11.25
4.60 52-week range 11.72
YTD
+77.56%
1 year
+137.39%

5D +1.06 (+10.32%)

1011WedFriMonTue11.33
Market cap
99.28M
Revenue (ttm)
23.22M
Profit margin
-17.44%
EPS (ttm)
0.19
Shares out
8.91M
P/E ratio
57.47
Forward P/E
-42.82
YTD return
+77.56%
1-year return
+137.39%
Volume
18.75K
Avg volume
13.32K
Open
11.06
Previous close
11.19
Day's range
10.31 – 11.25
52-week range
4.60 – 11.72
Beta
0.57
50-day average
3.93
200-day average
4.28

Key statistics

Enterprise value
42.71M
Price / sales
1.81
Price / book
1.46
Revenue growth
54.90%
Free cash flow
522.36K
Total cash
1.32M
Total debt
15.84M
Return on equity
-16.10%
Short % of float
0.06%

Fundamental scorecard

11 of 25 checks passed on ICCC’s reported financials

ValueGrowthProfitabilityHealthDividend

11of 25 checks passed

  • Value 1 of 5
  • Growth 2 of 5
  • Profitability 3 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ICCC Revenue — quarterly 8.04M
ICCC Net income — quarterly 952.51K
ICCC EPS — quarterly 0.10

Earnings

ICCC recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2024Sep 1, 20240.00-0.09——
Aug 13, 2024Jun 1, 20240.00-0.20——
May 14, 2024Mar 1, 20240.00-0.06——
Feb 27, 2024Dec 1, 20230.00-0.15——
Nov 13, 2023Sep 1, 20230.00-0.12——
Aug 10, 2023Jun 1, 20230.00-0.18——

Upgrades / downgrades

ICCC analyst upgrades and downgrades
DateFirmActionFromTo
Jul 13, 2020Aegis Capitalinit—Buy

About ImmuCell Corporation

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
immucell.com

News

Your note

Sign in to keep a note on ICCC — it syncs with the Stock Master app.

Institution ownership

ICCC institution ownership
Holder% heldSharesValueReported
Cresset Asset Management, LLC2.96%264,0021.24MSep 29, 2024
Vanguard Group Inc2.53%225,5951.06MSep 29, 2024
Renaissance Technologies, LLC1.68%149,489704.09KSep 29, 2024
Bleichroeder LP1.14%101,594478.51KSep 29, 2024
Dimensional Fund Advisors LP0.82%72,682342.33KSep 29, 2024
Morgan Stanley0.71%63,516299.16KSep 29, 2024

Fund ownership

ICCC fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.78%158,957748.69KSep 29, 2024
Vanguard Extended Market Index Fund0.75%66,638313.86KSep 29, 2024
Fidelity Extended Market Index Fund0.33%29,102137.07KOct 30, 2024
DFA U.S. Small Cap Value Series0.32%28,578134.60KJul 30, 2024
Fidelity Total Market Index Fund0.15%13,74764.75KOct 30, 2024
iShares Micro Cap ETF0.15%13,12761.83KOct 30, 2024